INVENTIVA (EPA:IVA) | Finanzwire

Basculer en Français

10590	Companies
224545	Keywords
153298	Articles
118786	Press releases

Home
Companies
INVENTIVA

PRESS RELEASE

published on 01/22/2025 at 22:00, 1 year 4 months ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Inventiva announces selection of LEGEND trial results evaluating lanifibranor and empagliflozin for oral presentation at EASL SLD Summit 2025, showing positive outcomes in MASH patients with T2D

Inventiva MASH Lanifibranor Empagliflozin LEGEND Trial
BRIEF

published on 12/17/2024 at 22:05, 1 year 5 months ago

Inventiva to present at the JP Morgan Healthcare Conference

Investors Inventiva NASH Lanifibranor JP Morgan Healthcare
PRESS RELEASE

published on 12/17/2024 at 22:00, 1 year 5 months ago

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference with CEO Frédéric Cren providing a corporate overview and engaging in investor meetings

Biopharmaceutical Inventiva J.P. Morgan Healthcare Conference Frédéric Cren Metabolic Dysfunction
BRIEF

published on 12/12/2024 at 22:05, 1 year 6 months ago

Inventiva Announces Shareholders’ Meeting Vote Results

Voting Results Shareholders' Meeting Biopharmaceutical Resolutions Inventiva
PRESS RELEASE

published on 12/12/2024 at 22:00, 1 year 6 months ago

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
Inventiva announces voting results of Combined Shareholders' General Meeting on December 11, 2024. All resolutions were adopted except the 59th resolution

Voting Results Shareholders' Meeting Clinical-Stage Biopharmaceutical Inventiva NASH
BRIEF

published on 11/21/2024 at 22:05, 1 year 6 months ago

Inventiva's Financial Overview for Q3 2024

Financial Results Cash Position Equity Raise Royalty Certificates R&D Expenses
PRESS RELEASE

published on 11/21/2024 at 22:00, 1 year 6 months ago

Inventiva reports 2024 Third Quarter Financial Information¹
Inventiva reports strong financial position with €13.9 million cash at September 30, 2024. R&D expenses down 10% in 2024. Key milestones and future conference participation announced

Financial Information Cash Position Inventiva R&D Expenses Key Milestones
BRIEF

published on 11/20/2024 at 22:05, 1 year 6 months ago

Inventiva Combined General Meeting: Documents Available

Funding Documents General Assembly Inventiva NASH
PRESS RELEASE

published on 11/20/2024 at 22:00, 1 year 6 months ago

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
Inventiva reports total voting rights and shares as of November 4, 2024, in accordance with Article R. 22-10-23 of the French Commercial Code. The company is a clinical-stage biopharmaceutical with a focus on oral small molecule therapies

Shares Total Voting Rights Clinical-Stage Biopharmaceutical Inventiva MASH/NASH
PRESS RELEASE

published on 11/20/2024 at 22:00, 1 year 6 months ago

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Inventiva announces availability of preparatory documents for Combined General Meeting on December 11, 2024. Shareholders can participate in person or request documents electronically. Detailed resolutions and meeting information provided

Shareholders Resolutions Preparatory Documents Combined General Meeting Inventiva

Accesswire

Published on 06/17/2026 at 16:55, 4 hours 48 minutes ago

Snipp Interactive Named a Representative Vendor in the Gartner(R) 2026 Market Guide for Loyalty Program Vendors
Published on 06/17/2026 at 16:45, 4 hours 58 minutes ago

Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean
Published on 06/17/2026 at 14:30, 7 hours 13 minutes ago

Solitario Advances 2026 Ponderosa Drilling Program
Published on 06/17/2026 at 14:00, 7 hours 43 minutes ago

CHAR Tech Reminds Shareholders of June 18 Investor Update Call
Published on 06/17/2026 at 14:00, 7 hours 43 minutes ago

Trifecta Gold Increases Private Placement

View all ACCESSWIRE

EQS Group

Published on 06/17/2026 at 19:10, 2 hours 33 minutes ago

Africa Finance Corporation and Leading Italian Institutions Sign Strategic Cooperation Agreements at AFC-Italy Forum to Mobilise Capital and Accelerate Industrial Development Across Africa
Published on 06/17/2026 at 18:40, 3 hours 3 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/17/2026 at 18:36, 3 hours 7 minutes ago

BILENDI: Bilendi announces that Euroland Corporate has initiated coverage of its shares
Published on 06/17/2026 at 18:23, 3 hours 20 minutes ago

EQS-Adhoc: Ludwig Beck am Rathauseck-Textilhaus Feldmeier AG: Conclusion of a delisting agreement with Bayerische Gewerbebau AG
Published on 06/17/2026 at 18:05, 3 hours 38 minutes ago

WACACO LAUNCHES PRESTINA, A PATENTED MANUAL COFFEE BREWER THAT TURNS THE CUP INTO THE PRESS

Les Echos

Published on 06/17/2026 at 17:40, 4 hours 3 minutes ago

Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 12 hours 58 minutes ago

Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
Published on 06/16/2026 at 11:44, 1 day 9 hours ago

Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 1 day 22 hours ago

BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 2 days 2 hours ago

Reporting on share buyback transactions carried out between June 8 and June 11, 2026

View all LES ECHOS COMFI WIRE